SciELO - Scientific Electronic Library Online

vol.36 número 1Una enfermedad prevenible: el accidente cerebrovascular en la fibrilación auricular no valvular ¿Qué lugar ocupan los nuevos anticoagulantes orales?Vasculitis Paraneoplásica: Presentación de 2 casos clínicos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



Links relacionados


Archivos de Medicina Interna

versión impresa ISSN 0250-3816versión On-line ISSN 1688-423X


VALVERDE, Marcelo et al. Hepatorenal Syndrome: clinical approach and therapeutic strategy. Arch. Med Int [online]. 2014, vol.36, n. 1, pp.17-27. ISSN 0250-3816.

Hepatorenal syndrome (HRS) is defined as the onset of renal failure without an identifiable cause in a cirrhotic patient. According with the installation speed and the severity of the renal failure, two types are described: type I and type II. Type I is characterized by a rapid and progressive deterioration of renal function with an ominous prognosis. Type II, presents with an insidious and less severe development of renal failure, but always bears a poor short-term prognosis. Although the implementation of therapeutic strategies has a clear impact on the prognosis, the median overall survival of these patients is approximately 3 months (2 weeks for type I HRS vs. 4 to 6 months for type II HRS). Since there are no specific tests for the diagnosis, it is based on a combination of clinical and laboratory data as well as the exclusion of other kinds of renal injury. Systemic vasoconstrictors drugs analogues of vasopressin combined with albumin are the treatment of choice before liver transplantation, which constitutes the definitive treatment of this entity.

Palabras clave : Hepatorenal syndrome; Renal failure; Cirrhosis.

        · resumen en Español     · texto en Español


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons